The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 5)
Biosample and Tissue Resource, 2013
Mutations in the glucocerebrosidase (GBA) gene are the most common genetic risk factor for Parkinson's disease (PD). These mutations are present in approximately seven percent of PD patients. The aim of this project is to determine whether the GBA protein (coded by the GBA gene) is altered in the majority brains of sporadic (cause unknown) PD patients without these...
Research Grant, 2011
Loss of dopamine-producing neurons in Parkinson's disease (PD) is accompanied by inflammation in surrounding support cells, called glial cells. This inflammatory state in glial cells leads to production of toxic substances that further damage neurons, leading to a viscous cycle of inflammatory damage that ultimately worsens the progression of the disease. New evidence in expe...
Researchers: Ronald Tjalkens, PhD
MJFF Research Grant, 2011
Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD
Oxidative stress has been implicated in the etiology of Parkinson's disease (PD). Under such conditions, the transcription factor NF-E2-related factor (Nrf2) binds to antioxidant response element (ARE) to induce antioxidant and phase II detoxification enzymes. Numerous studies suggest that activation of the Nrf2-ARE pathway in the brain confers protection to vulnerable neuron...
Researchers: Martin Martinov, PhD
MJFF Research Grant, 2009
Mutations in the LRRK2 gene are the most common genetic cause of classic or typical Parkinson’s disease (PD). One mutation, G2019S, is especially frequent in Jewish (about 14%) and North African Berber (30-40%) patients with PD. Not all LRRK2 mutation carriers, however, develop PD. Studies of Jewish LRRK2 carriers estimate that only 25-35% of gene carriers ever develop sympto...
The Phase III trial is currently recruiting. Learn more: https://foxtrialfinder.michaeljfox.org/trial/4305/
Urate - a natural metabolite and major antioxidant in humans - is emerging as a predictor of both the risk and the progression of typical Parkinson's disease (PD). Studies of healthy individuals have linked urate levels in the upper normal range to a reduced risk of de...